# A Study to Learn More About Treatment With Damoctocog Alfa Pegol, How it is Used in Every Day Practice ("Real-World"), and How Satisfied People Who Receive Damoctocog Alfa Pegol Are in United States (US) Hemophilia Treatment Centers

> **NCT05395858** · — · TERMINATED · sponsor: **Bayer** · enrollment: 14 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **OTHER:** No intervention

## Key facts

- **NCT ID:** NCT05395858
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2023-01-17
- **Primary completion:** 2023-11-06
- **Final completion:** 2023-11-06
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Bayer business decision to close the REAL study based on the following: Target objective of enrolling at least 20 patients into the retrospective part failed; Not enough available data that would be a meaningful addition to the literature.
- **Last updated:** 2023-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05395858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05395858, "A Study to Learn More About Treatment With Damoctocog Alfa Pegol, How it is Used in Every Day Practice ("Real-World"), and How Satisfied People Who Receive Damoctocog Alfa Pegol Are in United States (US) Hemophilia Treatment Centers". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT05395858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*